Non-muscle Invasive Bladder Cancer research hub
12 indexed studies · 7 currently recruiting
- recruitingPHASE1
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
This study looks at a new medicine, PF-08052667, for a type of bladder cancer that hasn't spread into the muscle. It checks if the medicine works alone or with other treatments like BCG and sasanlimab, especially for cancer that has come back.
United States · France · Israel - recruitingHuman Pharmacology (Phase I)- Other
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
This study is looking into a new treatment called UGN-301 for people in the UK with non-muscle invasive bladder cancer (NMIBC) that has returned. It's a very early stage study to find a safe dose and see how the treatment works.
Italy · Spain - recruitingTherapeutic exploratory (Phase II)
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer
This study is looking into a new combination treatment for bladder cancer that hasn't spread into the muscle. It combines a standard treatment, BCG, with a new experimental drug called N-803. The aim is to see if this new combination works better at getting rid of the cancer.
Germany - recruitingPHASE1, PHASE2
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
This study is testing a new gene therapy, EG-70, for bladder cancer that hasn't responded to standard treatments. It aims to see how safe and effective it is for different types of non-muscle invasive bladder cancer.
United States · Australia · Canada - recruitingHuman Pharmacology (Phase I)- Other
A study of enfortumab vedotin given in the bladder for treatment of patients with non-muscle invasive bladder cancer (NMIBC).
This study is looking at a new treatment called enfortumab vedotin for bladder cancer that hasn't spread into the muscle. The medicine is put directly into the bladder to see if it can help people with this type of cancer.
France · Spain · Germany - recruitingPHASE1, PHASE2
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
This study is testing a new medicine, Sacituzumab Tirumotecan, for a type of bladder cancer that hasn't spread into the muscle. Researchers want to find a safe dose and see how well it works when given directly into the bladder.
United States · Canada · France - active not recruitingPHASE3
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
This study looked at a new medicine called sasanlimab for early-stage bladder cancer that hasn't spread. It compared sasanlimab with or without BCG, a common bladder cancer treatment. The goal was to see how safe and effective sasanlimab is in preventing the cancer from coming back.
United States · Australia · Belgium - active not recruitingPHASE3
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
This study is testing a new combination treatment for a type of bladder cancer that hasn't spread deep into the bladder wall. It's comparing a new drug called Durvalumab with the standard treatment to see if it's more effective and safe.
Australia · Austria · Belgium - active not recruitingPHASE3
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
This study looks at a new treatment called cretostimogene grenadenorepvec for a type of bladder cancer that hasn't spread into the muscle. It compares giving this treatment after surgery to just monitoring patients. The aim is to see if the new treatment can stop the cancer from coming back.
United States · Canada - recruitingPHASE2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
This study is looking at a new treatment called TARA-002 for adults with a type of bladder cancer that hasn't spread into the muscle. It wants to check how safe and effective this treatment is using a liquid that goes directly into the bladder.
United States · Argentina · Brazil - active not recruitingPHASE3
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
This study is testing a new treatment, cretostimogene, for a type of bladder cancer that hasn't responded to usual treatments like BCG. It's for people with non-muscle invasive bladder cancer, specifically high-grade types. The aim is to see how well it works.
United States · Australia · Canada - authorisedPhase III and phase IV (Integrated)
PROSPECTIVE RANDOMISED CLINICAL TRIAL TO EVALUATE THE EARLY RECURRENCE RATE IN NON-MUSCLE INVASIVE BLADDER CANCER BETWEEN THE USE OF CHEMOHYPERTHERMIA (QH) WITH MITOMYCIN-C PRIOR TO TRANSURETHRAL BLADDER RESECTION IN A MAJOR OUTPATIENT SURGERY PROGRAMME AND TREATMENT WITH MITOMYCIN-C IN NORMOTHERMIA POST-RESECTION.
This study looks at treating bladder cancer that hasn't spread to the muscle. It compares two ways of giving medicine into the bladder to stop the cancer coming back: one uses heat with the medicine before surgery, and the other uses the medicine without heat after surgery.
Spain